NCT03345095 2025-07-01
MIRAGE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
Clinical Trials
12 trialsNCT05050305 2024-07-16
Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04341311 2024-02-15
DIPG
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03727841 2022-07-27
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed
NCT04644107 2020-11-25
Expanded Access for Marizomib
Celgene
No longer available
NCT00461045 2017-12-19
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Celgene
Phase 2 Completed
NCT00396864 2017-11-22
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
Celgene
Phase 1 Completed
NCT00629473 2017-11-22
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
Celgene
Phase 1 Completed
NCT00667082 2017-11-22
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Phase 1 Completed
NCT02103335 2017-11-22
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed